Sidoti downgraded Surmodics to Neutral from Buy with a $43 price target after the company entered into a definitive agreement to be acquired by GTCR for $43.00 per share in cash.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRDX: